NCT01298531

A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis

A Multi Centre, Double Blind, Placebo-controlled Study to Evaluate the Non Steroidal Anti-inflamatory Drugs (NSAIDS) Sparing Effect of Etanercept in Adult Subjects With Axial Involvement of Spondyloarthritis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will compare the Non Steroidal Anti-Inflammatory Drugs (NSAIDs) sparing effect of etanercept with that of placebo in adult subjects with axial Spondyloarthritis.

Conditions

• Axial Spondyloarthritis

Interventions

Type	Name	Description
DRUG	etanercept	etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
DRUG	etanercept	etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
DRUG	placebo	placebo subcutaneous (SC) injections once weekly for 8 weeks.

Timeline

• Start date: 2011-05-01
• Primary completion: 2013-01-01
• Completion: 2013-04-01
• First posted: 2011-02-17
• Last updated: 2014-07-29
• Results posted: 2014-07-29

Locations

19 sites across 1 country: France